Targeting the Immune-Neurovascular Interface to Ameliorate Pericyte Dysfunction with a Multifunctional Peptide–Drug Conjugate Nanoprodrug for Multiple Sclerosis Therapy
ACS Nano · 2026
DOI: 10.1021/acsnano.6c11475 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Yongkang Mu und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, National Key Laboratory of Advanced Drug Formulat…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Pericytes, Peptides, Prodrugs. Die Arbeit nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, State Key Laboratory of Neurology and Oncology Drug Development, National Center for Translational Medicine Shanghai SHU Branch.
Abstract (Originalsprache)
Pericyte dysfunction triggers blood–brain barrier (BBB) disruption and subsequent aberrant immune infiltration in multiple sclerosis (MS), yet targeted interventions remain lacking. Here, we engineered a dual-functional fusion peptide (VLC) for pericyte targeting and therapeutic intervention and subsequently conjugated it with luteolin to construct a peptide–drug conjugate (PDC)-based ROS-responsive nanoprodrug (VLC@Lut-NPs). This system significantly suppressed MMP-9 overactivation and mitigated neuroinflammation. To optimize the pharmacokinetic profile of the PDC nanotherapeutic, we adopted subcutaneous administration, achieving a prolonged circulation half-life and enhancing brain drug accumulation (AUCbrain) by 2.65-fold compared with intravenous injection. In two MS models, VLC@Lut-NPs restored pericyte homeostasis, reinforced BBB integrity, attenuated aberrant peripheral immune infiltration, and ultimately promoted myelin repair and regeneration. Notably, a once-every-other-day subcutaneous regimen outperformed daily intravenous administration. By bridging peripheral immunity and the neurovascular unit, this work identifies pericytes as a central regulatory node and establishes a pericyte-targeted PDC nanoplatform for durable MS treatment, highlighting its translational potential as a complementary strategy to conventional immunomodulatory approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, National Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Shanghai201203, P. R. China.
- Institute of Diagnostic and Interventional Radiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai200233, P. R. China.
- Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai200433, P. R. China.
- Key Laboratory of Molecular Neurobiology of Ministry of Education, Naval Medical University, Shanghai200433, P. R. China.
ORCID-Profile: Peng Yang, Qizhi Zhang
Förderung
- National Natural Science Foundation of China
- State Key Laboratory of Neurology and Oncology Drug Development
- National Center for Translational Medicine Shanghai SHU Branch
Zitieren
APA
Mu, Y., Wen, K., Zhou, L., Gu, Z., Wang, T., Li, Y., Yang, X., Liu, X., Zhang, X., Chi, W., Zhang, N., Yang, P., & Zhang, Q. (2026). Targeting the Immune-Neurovascular Interface to Ameliorate Pericyte Dysfunction with a Multifunctional Peptide–Drug Conjugate Nanoprodrug for Multiple Sclerosis Therapy. ACS Nano. https://doi.org/10.1021/acsnano.6c11475
Vancouver
Mu Y, Wen K, Zhou L, Gu Z, Wang T, Li Y, et al. Targeting the Immune-Neurovascular Interface to Ameliorate Pericyte Dysfunction with a Multifunctional Peptide–Drug Conjugate Nanoprodrug for Multiple Sclerosis Therapy. ACS Nano. 2026. doi:10.1021/acsnano.6c11475
BibTeX
@article{Mu2026,
author = {Mu, Yongkang and Wen, Kaichao and Zhou, Lingling and Gu, Zhiyong and Wang, Tianying and Li, Yixian and Yang, Xiyu and Liu, Xuan and Zhang, Xinyi and Chi, Wenya and Zhang, Nianni and Yang, Peng and Zhang, Qizhi},
title = {Targeting the Immune-Neurovascular Interface to Ameliorate Pericyte Dysfunction with a Multifunctional Peptide–Drug Conjugate Nanoprodrug for Multiple Sclerosis Therapy},
journal = {ACS Nano},
year = {2026},
doi = {10.1021/acsnano.6c11475}
}
EUVIMED